Article Text

Download PDFPDF

Cutting edge methodology
P1-60 European guidelines for colorectal cancer screening—initial standards
  1. L von Karsa1,
  2. S Moss2,
  3. R Ancelle-Park3,
  4. H Brenner4,
  5. P Armaroli5,
  6. C Senore5,
  7. J Patnick6,7,
  8. C Herrmann1,
  9. T Lignini1,
  10. S Ducarroz1,
  11. N Segnan5
  1. 1International Agency for Research on Cancer, Lyon, France
  2. 2Institute of Cancer Research, Sutton, Surrey, UK
  3. 3Direction Générale de la Santé, Paris, France
  4. 4German Cancer Research Centre, Heidelberg, Germany
  5. 5CPO Piemonte and S.Giovanni University Hospital, Turin, Italy
  6. 6NHS Cancer Screening Programmes, Sheffield, UK
  7. 7Oxford University Cancer Screening Research Unit, Oxford, UK


Introduction Colorectal cancer (CRC) is the 4th most common cause of cancer death worldwide. The efficacy of screening in reducing CRC mortality has been proven in RCTs. The EU recommends population-based screening with appropriate quality at each step in the screening process. Evidence-based, multidisciplinary European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis have been developed by experts and will be published shortly by the European Commission. The EU Guidelines include a summary table of performance standards in CRC screening.

Methods A multidisciplinary, pan-European group of experts in implementation, evaluation and quality assurance of colorectal cancer screening led by an editorial board drafted and revised the guidelines outline and key clinical questions covering the entire screening process. An expert literature group provided additional scientific support in defining the questions, conducting the respective literature reviews and evaluating the evidence. The bibliographic searches (Medline, Embase, Cochrane Library) covered the years 2000–2008. In selected cases, references not identified by the above process were included in the evidence base, for example, relevant articles published after 2008 identified by the authors.

Results For 13 parameters sufficient evidence was found from published trials and the experience in implementation of population-based screening programmes to achieve consensus on recommended targets across the EU.

Conclusions Initial performance standards have been developed which are suitable for a pan-European setting. Programmes should monitor numerous additional parameters to maintain and continuously improve quality. All standards should be constantly reviewed and revised accordingly with regard to results achieved and best clinical practice.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.